account adjust acquisition-rel cost certain
signific item
keytruda one power asset pharma done great job
develop mani franchis flat declin keytruda off-set
pressur might drive differenti growth share reason
attract valu base prospect greater pipelin visibl would help
swing pendulum posit direct
standout result present doubl forecast keytruda
share metastat nsclc ad keytruda
sale estim year keytruda sale forecast impli
becom one success drug ever support keytruda
strong posit mani tumor hand competit unrel
io landscap shift often futur far certain
ep estim increas vs guidanc
consensu vs consensu
impli ep compound-annual-growth-rate vs industri
averag price target rais ep given
rais ep outlook
sale estim increas vs guidanc
impli sale compound-annual-growth-rate vs industri averag keytruda expect
leader mani tumor metastat set beyond lung includ melanoma
head neck gastric bladder tripl neg breast cancer colorect cancer
tumor affect patient project
event includ truda approv cervic pdufa r/
 mediastin b-cell lymphoma pdufa lynparza approv ovarian eu
brcam metastat breast cancer jp lynparza file brcam ovarian
cancer brcam metastat breast cancer doravirin approv hiv pdufa
told keytruda readout next month
compani global big cap pharma univers smallest number
publicli reveal pipelin agent compani next fewest
believ key stock perform greater pipelin visibl
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market remicad zetia
vytorin cubicin nasonex biosimilars/gener competit pressur isentress
zostavax believ risk balanc opportun therefor remain market
perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
lynparza data/fil ovarian
oper margin improv
keytruda data and/or uptak lung
posit expect
new product unabl off-set nasonex
vytorin/zetia cubicin patent
expir competit pressur
zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
estim market share compani non-smal cell lung carcinoma nsclc melanoma
cowen compani
estim market share compani head neck cancer gastric cancer
cowen compani
estim market share compani bladder cancer tripl neg breast cancer tnbc
cowen compani
cowen compani
cowen compani
detail see cowen pharmaceut puls march link
time frameev primari complet juli crcfull data mono lung similar met os apr ndata squamou nsclc epacadostat idoi full data ph melanoma miss pfslynparza w/azn phase data brcam ovarian cancer data pancreat cancer data vabpregulatorydoravirineu approv hiv mono tablet fdc w/tenofovir lamivudin pdufa vaccineregulatori file januvuanext step label inlcud teco data absenc cv risk rcv approv refractory/relaps mediastin b-cell lymphoma pdufa approv post chemo cervic cancer pdufa w/azn eu approv ovarian cancer posit chmp feb file brcam ovarian cancer file brcam metastat breast cancer approv brcam metastat breast cancer cowen
cowen compani
totalgrosssg aoper non-pretaxtaxnety/ysharessal chgp mm sl mm slsp opp rateincomeep reflect restat defin benefit cost present outsid oper expens reflect non-op income/expens cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
cowen compani
 patent expir glenmark enter month exclusivityzetia patent expir ezetimibecozaar/hyzaar arb hypertens gener competitionvytorin exclus laps patent expir ezetimibe/simvastatin improve-it achiev endpoint garner fda labelintegrilin revenu repurchas milleniumzocor cholesterol reduct patent expir develop riociguat solubl guanyl cyclas sgc modul approv eu pah cteph japan phase heart failur victoria ref-hf studi underway part bayer zetia lipitor market eu market patent expir littl eros japan despit patent market bridion market eu japanbridion sugammadex anesthesia revers suvorex insomnia orexin neuropeptid approv us japan like tier coverag yet file eu schizophrenia phase iiremeron antidepress patent expir januari major sale ex-u maxalt/maxalt mlt patent expir maxalt/maxalt mlt patent expir eumaxalt/maxalt mlt agonist anesthesia patent expir cowen
cowen compani
 share qd market unlik blunt erosionisentress qd approv eu hiv integras inhibitor treatment resist nave approv gilead gsk tivicay pose competitionnoxafil patent expir eu patent expir posaconazol oral antifung approv prophylaxi oral candidiasi cubicin advers court decis allow gener first gener teva launch sale nv modest royaltiescubicin cubist acquir launch competit landscap pressureszepati launch eu japan competit landscap pressureszepati hepat grazoprevir proteas inhibitor elbasvir competit landscap ceftolozane/tazobactam ww right ex asia-pacif gram neg infect approv phase habp/vabp bezlotoxumab tx difficil associ diarrhea cdad approv medarex/ma biolog difficil tedizolid gram posit infect launch phase habp/vabp bacteri pneumonia relebactam imipenem/cilastatin bacteri infect phase cmv prophylaxi transplant patient nnrti hiv posit phase data croi dose qd good safeti file roch pegasys/copegu pressur new drug clip durat therapyintron support use oncolog applicationsribavirin/rebetol older modalityintron substanc patent expir formul patent expir settlement allow gener launch aug ou patent expiredcancida antifung qd iv new indic price share eros due competitioninvanz patent expir compound composit invanz broad spectrum carbapenem oral im iv qdprimaxin emerg market-drivenprimaxin bolster sale effort blunt eros patent expir proteas inhibitor aid stocrin certain fgn mkt patent exp older antibioticstot cowen
cowen compani
 golimumab ra pa uc approv eu canadaremicad crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketsarcoxia approv market countriestot approv tumor type includ melanoma lung chl bladder msi-hkeytruda eu approv melanoma lung chl bladderkeytruda antibodi mani tumor type saha cutan t-cell lymphoma roll-out underway clinic trial underwayemend aprepit substanc antagonist emesi patent exp oral iv franchis oral/ivtemodar teva launch gener gener japan pat exp eu temodar chemotherapeut aa gbmazn lynparza/selumetinib record sale net cog sg record linetot gener launch over-the-counter product also pressurenasonex gener eu allerg rhinitisdulera asthma market copd longer pursu dulera launch copd four market asthma market dulera mometasone/formoterol competit dynam pressuresingulair patent expir patent expir eu includ month pedi exclus japansingulair asthma phase cough includ cough idiopath pulmonari fibrosi phase iiasmanex market asmanex market countriesasmanex asthma dri powder qd inhal corticosteroid patent devic formul expir beta agonist asthma cfc hfa complet cowen
cowen compani
 continuedclarinex small market retainedclarinex claritin rx/otc sold bayer ag tax part consum transact close asthma older product europetot nrx share patent expir pedi exclus could add monthsjanuvia patient expir exclus could add month januvia qd antidiabet competit threat given proven cv ertugliflozin diabet inhibitor w/ approv mono ertugliflozin/sitagliptin ertugliflozin/metformin omarigliptin diabet qweek inhibitor market japan file plan diabet mellitu insulin glargin biosimilar file approv eu diabet mellitu dual agonist antibodi phase iitot competit gsk shingrix prompt zostavax declin sale reflect dissolut spmsd jv ad herp zoster vaccin adult year singl sq dose plu booster investigatedproquad mmr ii varivax mmr ii varivax sale reflect dissolut spmsd jv ad mmr ii varivax could support health initiativesrotateq sale reflect dissolut spmsd jv ad rotaviru vaccin oral liquid good safeti profil market ww competit gskgardasil/gardasil approv year old femal male sale gardasil two dose approv fda/cdcgardasil/gardasil sale reflect dissolut spmsd jv ad approv two dose regimen china launch boostsgardasil/gardasil hpv vaccin borrow cdc stockpil refil hexaval combin pediatr vaccin approv eu nda issu inactiv herp zoster vaccin phase pneumoconjug vaccin phase iipneumovax prevnar pressuringpneumovax pneumococc vaccin adultstot cowen
cowen compani
 psoriasi moder potenc steroid patent exp compound cream lotion implanon/nexplanon implant contracept patent expir juli progesteron/estrogen market eu exclus pursu corifollitropin alpha infertil market eu exclus pursu nuvar patent expir april contracept vagin contracept patent expir septemb aq aq aq follitropin beta inject patent expir june oral contracept patent expir decemb contracept patent expir septemb oral contracept patent expir march contraception/women cowen
cowen compani
 bph gener competit fosamax osteoporosi gener launch patent expir bald domin small acceler time upper lower gi recoveri post surgeri cubistoth ivomec merial othertot healthanim bravecto oral approv may key driveranim mainli feed animalsanim busi spin/split/sal possibl guidanc cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
